Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Bolt Biotherapeutics Dividend Announcement
• Bolt Biotherapeutics announced a quarterly dividend of $0.09 per ordinary share which will be made payable on 2014-10-02. Ex dividend date: 2014-08-29
• Bolt Biotherapeutics's trailing twelve-month (TTM) dividend yield is -%
Bolt Biotherapeutics Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2014-08-29 | $0.09 | quarterly | 2014-10-02 |
2014-06-10 | $0.09 | quarterly | 2014-07-09 |
2014-03-03 | $0.09 | quarterly | 2014-04-02 |
2013-12-30 | $0.09 | quarterly | 2014-01-15 |
2013-09-03 | $0.09 | quarterly | 2013-10-03 |
2013-06-03 | $0.07 | quarterly | 2013-07-05 |
2013-03-05 | $0.07 | quarterly | 2013-04-04 |
2012-11-30 | $0.07 | quarterly | 2012-12-18 |
2012-09-04 | $0.07 | quarterly | 2012-10-04 |
2012-06-04 | $0.05 | quarterly | 2012-07-06 |
2012-03-06 | $0.05 | quarterly | 2012-04-05 |
Bolt Biotherapeutics Dividend per year
Bolt Biotherapeutics Dividend growth
Bolt Biotherapeutics Dividend Yield
Bolt Biotherapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Bolt Biotherapeutics stock? Use our calculator to estimate your expected dividend yield:
Bolt Biotherapeutics Financial Ratios
Bolt Biotherapeutics Dividend FAQ
Other factors to consider when evaluating Bolt Biotherapeutics as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Bolt Biotherapeutics stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Bolt Biotherapeutics's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Bolt Biotherapeutics publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Bolt Biotherapeutics distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Bolt Biotherapeutics are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Bolt Biotherapeutics sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Bolt Biotherapeutics distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Bolt Biotherapeutics declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Bolt Biotherapeutics's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Bolt Biotherapeutics's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.